---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-006985"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:36:17.502213+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ChromaDex provides 2022 outlook: net sales +15-20% YoY; Tru Niagen revenue $56.7M in 2021

## Summary
- 2021 net sales $67.4M (+14% YoY); Tru Niagen sales $56.7M; gross margin 61.5%.
- 2022 guidance: net sales +15-20% YoY; gross margin ~60%; R&D spend up ~$2M; G&A down $5-6M.
- E-commerce 62% of sales; partnerships expanded with Walmart US and Watsons; new SinoPharm partnership for China.
- Cash $28.2M, zero debt; adjusted EBITDA excl. legal loss $(2.5)M in 2021; litigation expense largely behind.
- Pipeline includes next-gen NAD precursors (NRH, NAR) with 10+ granted patents; 20+ clinical studies supporting NAD+ boosting.

## SEC filing metadata
- accession: 0001628280-22-006985
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828022006985/0001628280-22-006985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828022006985/cdxc-20220323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-006985
- JSON: https://secwatch.observer/filing/0001628280-22-006985.json
- Plain text: https://secwatch.observer/filing/0001628280-22-006985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.